Article
Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients.
Oncogene - 1 May 2022
Bramhecha Yogesh M, Guérard Karl-Philippe, Audet-Walsh Étienne, Rouzbeh Shaghayegh, Kassem Ola, Pernet Erwan, Scarlata Eleonora, Hamel Lucie, Brimo Fadi, Divangahi Maziar, Aprikian Armen G, Chevalier Simone, Giguère Vincent, Lapointe Jacques
Abstract excerpt
Prostate cancer (PCa) metastases are highly enriched with genomic alterations including a gain at the 16p13.3 locus, recently shown to be associated with disease progression and poor clinical outcome. ECI1, residing at the 16p13.3 gain region, encodes Δ3, Δ2-Enoyl-CoA Delta Isomerase 1 (ECI1), a key mitochondrial fatty acid β-oxidation enzyme. Although deregulated mitochondrial fatty acid β-oxidation is known to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.